Event-Driven Stocks

Q32 Bio Inc.

QTTBNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 2 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$53.7M$0$1.2M$3.2M$34.0M$2.7M
Operating income$16.9M−$66.1M−$48.3M−$133.3M−$95.9M−$130.3M
Net income$29.8M−$47.7M−$53.7M−$5.0M−$95.8M−$128.7M
Total assets$61.8M$92.3M$47.1M$228.5M$211.7M$263.7M
Total liabilities$19.8M$86.7M$118.5M$50.5M$42.1M$67.7M
Equity$42.0M$5.7M−$182.9M−$130.7M$169.7M$196.0M
EPS (diluted)$2.42$-6.58$-153.96$-0.09$-1.73—
Shares out.12.2M58.1M57.7M57.4M50.5M45.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
31.5%
Net margin
55.5%
Return on equity
71.0%
Return on assets
48.3%
Return on capital (ROCE)
33.5%
Liabilities / assets
32.0%
Debt / equity
0.47×
Book value / share
$3.44
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-2.11distress
Accruals / assets
102.6%high accruals
Piotroski F-Score
5/8mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
61
/ 100
Profitability 100Growth n/aCatalyst 67Earnings quality 0Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 2 warning● 3 good
  • Altman Z″ in the distress zone
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Operating margin is positive
  • Strong return on equity (>15%)
  • Conservative leverage (liabilities < 50% of assets)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
3 acquisitions5 disposalsnet +174,466 shares · last 8
InsiderDateTypeSharesPrice
Violette Shelia M.Officer — Chief Scientific OfficerFeb 24, 2026Grant37,500$0.00
Morrison Jodie PopeOfficer — CEOFeb 24, 2026Grant132,000$0.00
Kalowski LeeOfficer — CFO and PresidentFeb 24, 2026Grant53,250$0.00
Kalowski LeeOfficer — CFO and PresidentFeb 25, 2026Sell3,995$4.51
Morrison Jodie PopeOfficer — CEOFeb 25, 2026Sell9,896$4.51
Violette Shelia M.Officer — Chief Scientific OfficerFeb 25, 2026Sell2,815$4.51
Morrison Jodie PopeOfficer — CEODec 2, 2025Sell22,506$3.46
Kalowski LeeOfficer — CFO and PresidentDec 2, 2025Sell9,072$3.46

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026632,7222.7-3.1%
Apr 30, 2026652,8151.6+70.7%
Apr 15, 2026382,3501.2-7.0%
Mar 31, 2026411,0111.2+17.3%
Mar 13, 2026350,5201.1-3.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)